Sionna Therapeutics Prices Upsized Initial Public Offering
The gross proceeds from the initial public offering are expected to be approximately $191 million, before deducting underwriting discounts and commissions and other offering expenses, and excluding ...
Fentanyl-laced marijuana, horse tranquilizer, and nitazenes listed as top emerging drug threats in US
Marijuana laced with fentanyl, the zombie drug xylazine, and nitazenes were listed as the top concerns people will face in the evolving drug ecosystem, during a Thursday hearing before the House ...
60 Degrees Pharma Announces Closing of $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
The aggregate gross proceeds to the Company from the offering were approximately $1.075 million, before deducting the placement agent fees and other offering expenses payable by the Company. The total ...
Trump Faces Pressure From US Industry Over China Tariff on Medicines
(Reuters) - President Donald Trump is facing pressure from U.S. hospitals and generic drugmakers to exempt medical goods from ...